Thiogenesis Therapeutics (TTI.V) on Wednesday said it appointed of Gilad Aharon to its board of directors.
Aharon is a co-founder and portfolio manager at Rosalind Advisors, a Toronto-based life-sciences institutional investor.
The appointment follows Rosalind Advisors' investment in Thiogenesis' recently completed, non-brokered private placement.
"Gil brings significant experience and depth of insight in the life sciences sector, and we look forward to working together in advancing TTI-0102," said chief executive Patrice Rioux.
The company's shares were last seen unchanged at $0.57 on the TSX Venture Exchange.